BioAdaptives, Inc. Establishes a Wholesale Division to Expand Marketing Presence in a USD 151.9 Billion Global Dietary Supplement Market
LAS VEGAS, NV, Dec. 08, 2022 (GLOBE NEWSWIRE) -- via – BioAdaptives, Inc (OTC BDPT) is pleased to announce the formation of a Wholesale Division to expand product sales beyond current online retail availability. The global dietary supplements market size was estimated to be USD 151.9 billion in 2021 and is expected to increase at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030.
Dr. Edward Jacobs, CEO BioAdaptives, Inc., states, “We are continuing to expand our marketing effort by establishing a Wholesale Division to increase the availability of our products beyond online sales. The demand for our products at wholesale prices is largely coming from our Affiliate program members who want to increase their participation through direct sales. We are also responding to a growing interest from retail stores, distributors and networks seeking to enlarge their product lines. With our expertise in product development, we are in a good position to participate in new, cooperative initiatives and believe that some of these could take advantage of selective low minimum “white label” arrangements and the possibility of creating custom natural supplement formulations.”
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.”
Additional information can be found at or in our SEC filings at
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
